Technical Analysis for ACOR - Acorda Therapeutics, Inc.

Grade Last Price % Change Price Change
grade A 21.85 -0.23% -0.05
ACOR closed down 0.23 percent on Monday, August 21, 2017, on 45 percent of normal volume.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical ACOR trend table...

Date Alert Name Type % Chg
Aug 21 Golden Cross Bullish 0.00%
Aug 21 Bollinger Band Squeeze Range Contraction 0.00%
Aug 18 Bollinger Band Squeeze Range Contraction -0.23%
Aug 16 180 Bullish Setup Bullish Swing Setup 1.39%
Aug 11 200 DMA Support Bullish 2.34%

Older signals for ACOR ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS under the Fampyra name internationally. In addition, it is developing Diazapam Nasal Spray, which is in NDA preparations for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase II clinical trials for cerebral palsy and post-stroke deficits; AC105, which is in Phase II clinical trials for the treatment of SCI and TBI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for SCI. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Is ACOR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 33.0
52 Week Low 13.6
Average Volume 718,182
200-Day Moving Average 20.3389
50-Day Moving Average 20.3555
20-Day Moving Average 21.6713
10-Day Moving Average 21.36
Average True Range 0.9367
ADX 22.48
+DI 25.73
-DI: 18.78
Chandelier Exit (Long, 3 ATRs) 20.8699
Chandelier Exit (Short, 3 ATRs) 22.4101
Upper Bollinger Band 22.7712
Lower Bollinger Band 20.5714
Percent B (%b) 0.58
Bandwidth 0.101508
MACD Line 0.3555
MACD Signal Line 0.4221
MACD Histogram -0.0666